| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2012: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000)
Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2010: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Research Abstract |
Substance-P (SP) enhances whole blood coagulation by activation of monocytes through neurokinin-1 receptors (NK1R) while the precise mechanisms of this phenomenon remain to beestablished. Effects of SP and a NK1R antagonist Spantide on the release of microparticles from human monocytic cells THP-1 were evaluated. Citrated human plasma, mixed with FITC-conjugated fibrinogen, was used for the marker of monocyte-derived procoagulant activity. The growth of thrombi generated in an experimental model for vein was also evaluated by fluorescence microscopy. Activation of THP-1 by SP increased the number of microparticles possessing tissue factor with procoagulant activity. Spantide significantly suppressed the release of microparticles from THP-1. The growth of thrombi in the vein model was significantly enhanced in the presence of THP-1.
|
